| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10008 | Avitinib maleate Featured | Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
|
| DC24068 | AVL-292 besylate Featured | AVL-292 besylate (Spebrutinib, CC-292) is a highly selective, covalent Btk inhibitor with IC50 of <1 nM. |
|
| DC5014 | AVL-292 Featured | AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
|
| DC11399 | AVN-492 Featured | AVN-492 is a very specific and highly-selective antagonist with picomolar affinity to 5-HT6R (Ki=91 pM). |
|
| DC8565 | AVN944 Featured | AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2. |
|
| DCAPI1313 | Avobenzone(Parsol 1789) | Avobenzone(Parsol 1789) |
|
| DC9436 | Avosentan | Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. |
|
| DC26015 | Deudextromethorphan Featured | AVP-786 is a novel, next-generation investigational drug product consisting of a combination of deudextromethorphan, and an ultra-low dose of quinidine. |
|
| DC20709 | AW-814141 | AW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β. |
|
| DC7071 | AWD 131-138(Imepitoin) Featured | AWD 131-138(Imepitoin) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models. |
|
| DC20243 | AWZ1066S Featured | AWZ1066S is a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis. |
|
| DC11802 | AX-024 free base Featured | AX-024 is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A. |
|
| DC10545 | AX-024 HCl Featured | AX-024 is the first-in-class inhibitor of T cell receptor (TCR); AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). |
|
| DC10649 | AX15836 Featured | AX15836 is a highly potent and selective ERK5 inhibitor. |
|
| DC10412 | AX20017 Featured | AX20017 is a small-molecule protein kinase G (PknG) inhibitor with an IC50 of 0.39 μM. |
|
| DCAPI1524 | Axitinib Featured | Axitinib is a non-selective receptor kinase inhibitor of Flt and Flk proteins. This compound also inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β and c-KIT with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is studied as an ant |
|
| DC20313 | Axl-IN-21 | Axl-IN-21 is a selective and potent inhibitor of wild-type Axl with IC50 of 2.2 nM. |
|
| DC23895 | AY-9944 Featured | AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme (IC50=13 nM). AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol. |
|
| DC11371 | AY-NH2 Featured | AY-NH2 is a peptide agonist of proteinase-activated receptor 4 (PAR4) that induces aggregation of rat and human platelets in vitro (EC50s = 15 and 60 μM, respectively). |
.png)
|
| DC23879 | AZ 4800 | AZ 4800 is a potent γ-secretase modulator that reduces Aβ40 and Aβ42 levels in HEK/APPswe cells with IC50 of 26 nM and 60 nM, also decreases Aβ39, whereas increases both Aβ37 and Aβ38.. |
|
| DC7367 | AZ-960 Featured | AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3. |
|
| DC20710 | AZ0108 | AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively. |
|
| DC11147 | AZ084 | AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM. |
|
| DC20314 | AZ-1 | AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity. |
|
| DC11975 | AZ 10397767 | AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0. |
|
| DC20711 | AZ10606120 dihydrochloride Featured | AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively. |
|
| DC12613 | AZ12204657 | AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM. |
|
| DC22724 | AZ12441970 | AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8. |
|
| DC12530 | AZ12601011 | AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM. |
|
| DC12531 | AZ12799734 | AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF |
|
